BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Ann Gastroenterol Surg 2020;4:100-8. [PMID: 32258974 DOI: 10.1002/ags3.12311] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Imamura T, Ohgi K, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Otsuka S, Tamura S, Uesaka K. The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.03.017] [Reference Citation Analysis]
2 Kameyama A, Ye J, Shimomura A, Yokohira M, Nakano-Narusawa Y, Yamakawa K, Mukai Y, Sanomura T, Okuyama H, Miyatake N, Furihata M, Tanaka C, Kitazawa R, Bando Y, Suemitsu Y, Kojima M, Mino-Kenudson M, Suzuki Y, Okano K, Matsuda Y. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Pancreatology 2021:S1424-3903(21)00570-6. [PMID: 34563448 DOI: 10.1016/j.pan.2021.09.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mima K, Hayashi H, Nakagawa S, Matsumoto T, Kinoshita S, Matsumura K, Kitamura F, Uemura N, Nakao Y, Itoyama R, Kaida T, Imai K, Yamashita YI, Baba H. Frailty is associated with poor prognosis after resection for pancreatic cancer. Int J Clin Oncol 2021. [PMID: 34235599 DOI: 10.1007/s10147-021-01983-z] [Reference Citation Analysis]
4 Yoshikawa T, Takenaka D, Ohno Y. Editorial for “ MRI Radiomics‐Based Nomogram From Primary Tumor for Pretreatment Prediction of Peripancreatic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: A Multicenter Study”. Magnetic Resonance Imaging. [DOI: 10.1002/jmri.28090] [Reference Citation Analysis]
5 Qu C, Zeng P, Wang H, Yuan C, Yuan H, Xiu D. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma. Magnetic Resonance Imaging. [DOI: 10.1002/jmri.28096] [Reference Citation Analysis]
6 Fukukura Y, Kumagae Y, Fujisaki Y, Nakamura S, Dominik Nickel M, Imai H, Yoshiura T. Extracellular volume fraction with MRI: As an alternative predictive biomarker to dynamic contrast-enhanced MRI for chemotherapy response of pancreatic ductal adenocarcinoma. Eur J Radiol 2021;145:110036. [PMID: 34814039 DOI: 10.1016/j.ejrad.2021.110036] [Reference Citation Analysis]
7 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mori S, Aoki T, Sakuraoka Y, Shimizu T, Yamaguchi T, Park KH, Matsumoto T, Shiraki T, Iso Y, Kubota K. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas 2021;50:744-50. [PMID: 34016892 DOI: 10.1097/MPA.0000000000001826] [Reference Citation Analysis]
9 Takeuchi S, Ambo Y, Kodama Y, Takada M, Kato K, Nakamura F, Hirano S. Preoperative embolization strategy for the combined resection of replaced right hepatic artery in pancreaticoduodenectomy: a small case series. Surg Case Rep 2022;8:49. [PMID: 35316851 DOI: 10.1186/s40792-022-01403-y] [Reference Citation Analysis]
10 Miyata T, Takamura H, Kin R, Nishiki H, Hashimoto A, Fujii Y, Miura S, Fujita J, Kaida D, Tomita Y, Nakamura N, Fujita H, Kinami S, Ueda N, Kosaka T. Pancreatic neuroendocrine tumor featuring growth into the main pancreatic duct and tumor thrombus within the splenic vein: a case report. J Surg Case Rep 2020;2020:rjaa155. [PMID: 32699600 DOI: 10.1093/jscr/rjaa155] [Reference Citation Analysis]
11 Hata T, Mizuma M, Iseki M, Takadate T, Ishida M, Nakagawa K, Hayashi H, Morikawa T, Motoi F, Unno M. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. J Hepatobiliary Pancreat Sci 2021;28:648-58. [PMID: 34022116 DOI: 10.1002/jhbp.993] [Reference Citation Analysis]
12 Shindo Y, Tokumitsu Y, Matsukuma S, Matsui H, Nakajima M, Suzuki N, Takeda S, Hoshii Y, Nagano H. Hepatic artery resection and reconstruction using the right gastroepiploic artery during pancreaticoduodenectomy in advanced pancreatic cancer. Langenbecks Arch Surg 2021. [PMID: 33847784 DOI: 10.1007/s00423-021-02120-0] [Reference Citation Analysis]
13 Jentzsch V, Davis JAA, Djamgoz MBA. Pancreatic Cancer (PDAC): Introduction of Evidence-Based Complementary Measures into Integrative Clinical Management. Cancers (Basel) 2020;12:E3096. [PMID: 33114159 DOI: 10.3390/cancers12113096] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Anger F, Döring A, van Dam J, Lock JF, Klein I, Bittrich M, Germer CT, Wiegering A, Kunzmann V, van Eijck C, Löb S. Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria. Ann Surg Oncol 2021;28:2325-36. [PMID: 32920720 DOI: 10.1245/s10434-020-09100-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Hue JJ, Sugumar K, Markt SC, Hardacre JM, Ammori JB, Rothermel LD, Winter JM, Ocuin LM. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy. Surgery 2021;170:207-14. [PMID: 33454134 DOI: 10.1016/j.surg.2020.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Hashimoto D, Satoi S, Ishikawa H, Kodera Y, Kamei K, Hirano S, Fujii T, Uemura K, Tsuchida A, Yamada S, Yamamoto T, Hirota K, Sekimoto M. Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study. Trials 2022;23. [DOI: 10.1186/s13063-021-05934-x] [Reference Citation Analysis]